Abstract: The present disclosure provides an evaluation device for evaluating a test subject's ability to identify an object, the evaluation device including: an input unit that receives input of the test subject; a display control unit that displays, on a display device, a test screen including a target object that the test subject should select and a non-target object that the test subject should not select; an input processing unit that determines whether or not a target object is selected on the basis of input of the test subject received by the input unit; and an evaluation unit that evaluates a temporal lobe function related to a visual recognition ability of the test subject on the basis of a response time required for the test subject to input when the input processing unit determines that the target object is selected.

Abstract: A particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%, and a process for preparation of the hollow particle, which includes granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.

Abstract: There are provided a system, an apparatus, a program, and a method for enabling objective evaluation of a three-dimensional cognitive ability through quantification. A three-dimensional cognitive ability of a measurement target person is evaluated by acquiring a position of a moving object, the position enabling identification of a distance between the moving object and the measurement target person, by receiving input of an active response of the measurement target person taken in response to a three-dimensional position of the object recognized by the measurement target person, and by determining whether the position of the object that is acquired and the response that is input correctly match.

Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.

Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.

Abstract: The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits ? particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.

Abstract: Provided is a method for assessing a correlation degree and an influence degree between a health degree in a health domain of concern and each preventive interventional action, based on biological information acquired in a time-series manner. The method comprises: acquiring biological information of an individual in a time-series manner; performing, based on the acquired biological information, an assessment of a health degree of the individual in a time-series manner; acquiring an intervention amount of each of one or more preventive interventional actions in a time-series manner; deriving a correlation degree and an influence degree between the time-series intervention amount of each of the one or more preventive interventional actions and the time-series health degree of the individual; and determining, as a relevant preventive interventional action, a preventive interventional action whose correlation degree is a given value or more, among the one or more preventive interventional actions.

Abstract: An object of the present invention is to provide an immunological detection method comprising carrying out an immunoreaction using an antibody to Mycoplasma pneumoniae protein P30, in which Mycoplasma pneumoniae is detected with high sensitivity. Provided is an immunological detection method for Mycoplasma pneumoniae using an antibody to Mycoplasma pneumoniae protein P30, the method comprising carrying out an immunoreaction in the presence of a polyoxyethylene alkyl amine. The immunological detection method that uses immunochromatography is also provided.

Abstract: The present invention provides an orally disintegrating tablet with improved photostability of a medicament unstable to light. The orally disintegrating tablet has an inner core and an outer layer that covers the surface of the inner core, wherein the inner core contains the medicament unstable to light and the outer layer contains a light-absorbing substance such as Red No. 2, Red No. 3, Yellow No. 4, Yellow No. 5, Blue No. 1, Red No. 3 aluminum lake, Yellow No. 4 aluminum lake, Yellow No. 5 aluminum lake, Blue No. 1 aluminum lake, Blue No. 2 aluminum lake, red ferric oxide, yellow ferric oxide, black iron oxide, carmine, or sodium copper chlorophyllin.

Abstract: The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.

Abstract: A problem to be solved by the present invention is to provide a method of inhibiting nonspecific reaction unique to feces in an immunochromatographic detection method in which a fecal sample is developed in an insoluble membrane to detect an analyte in the sample. It was found that nonspecific reaction caused by a fecal sample can be inhibited to accurately detect an analyte in the fecal sample by using a compound having in the molecule two or more carboxy groups. Particularly, it was found that nonspecific reaction unable to be inhibited by conventional methods can be inhibited for fecal samples of infants by using the sample diluent containing a compound having in the molecule two or more carboxy groups for the present invention, and the present invention was thereby completed.

Abstract: The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.

Abstract: The present invention relates to a stable ophthalmic suspension formulation comprising (R)-(?)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3?-pyrrolidine-1,2?,3,5?-tetrone, which is useful for treating a disease in posterior eye segment and the like, avoiding side-effects due to systemic exposure.

Abstract: A problem is to provide a method of inhibiting nonspecific reaction unique to feces in a detection method using immunochromatography developing a fecal sample in an insoluble membrane so as to detect an analyte in the sample, and an immunochromatographic test strip used therefor. The present invention provides a method of performing an immunochromatographic reaction in the presence of an anti-IgA antibody so as to detect an analyte in a fecal sample without being affected by nonspecific reaction, and an immunochromatographic test strip used therefor.

Abstract: The present invention relates to a stable ophthalmic suspension formulation comprising (R)-(?)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3?-pyrrolidine-1,2?,3,5?-tetrone, which is useful for treating a disease in posterior eye segment and the like, avoiding side-effects due to systemic exposure.

Abstract: The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.

Abstract: The purpose of the invention is to provide a press-coated orally-disintegrating tablet having a powder/granular material with poor formability in its inner core, which has an excellent disintegrability and a suitable hardness as a whole tablet. Furthermore, the invention is a press-coated orally-disintegrating tablet with an outer layer surrounding an inner core wherein the inner core has a thickness in the range of 30 to 80% per that of the whole tablet, and the outer layer comprises (a) microcrystalline cellulose, (b) a sugar or a sugar alcohol, and (c) one or more particular ingredients selected from the group consisting of crospovidone, starches, low-substituted hydroxypropylcellulose and carmellose.

Abstract: The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.

Abstract: A tablet containing droxidopa as an active ingredient in a proportion of 20-80 wt % relative to the total weight of the tablet, and characteristically containing at least one excipient selected from mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose, and corn-derived starch is provided. In addition, a preparation containing corn-derived processed starch or polyvinyl alcohol as a binder and the like, which is a stable tablet containing droxidopa as an active ingredient, is provided.

Abstract: The purpose of the present invention is to provide a press-coated orally-disintegrating tablet characterized by containing an inner core which has an excellent disintegratability in oral cavity and a suitable hardness as a whole tablet. The present invention relates to a press-coated orally-disintegrating tablet with an outer layer surrounding an inner core wherein the inner core has a thickness in the range of 10 to 90% per that of the whole tablet, and the outer layer comprises (a) microcrystalline cellulose, (b) an inorganic excipient, and (c) one or more particular ingredients selected from the group consisting of crospovidone, starches, low substituted hydroxypropylcellulose and carmellose.